Enlivex Therapeutics (NASDAQ:ENLV) Trading 2.4% Higher – Here’s What Happened

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was up 2.4% during trading on Thursday . The company traded as high as $1.61 and last traded at $1.52. Approximately 255,775 shares changed hands during mid-day trading, an increase of 154% from the average daily volume of 100,601 shares. The stock had previously closed at $1.49.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ENLV shares. EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Enlivex Therapeutics in a research note on Friday, September 27th.

Enlivex Therapeutics Stock Up 2.4 %

The company’s fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $1.47. The company has a market capitalization of $32.54 million, a price-to-earnings ratio of -1.29 and a beta of 1.04.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. Equities research analysts expect that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

Several institutional investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new stake in shares of Enlivex Therapeutics during the second quarter worth $2,415,000. Sigma Investment Counselors Inc. acquired a new position in Enlivex Therapeutics in the 3rd quarter worth $50,000. Finally, XTX Topco Ltd bought a new position in Enlivex Therapeutics during the 2nd quarter worth about $35,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.